{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T13:56:58Z","timestamp":1790603818842,"version":"4.1.0"},"reference-count":17,"publisher":"SAABRON PRESS","issue":"3","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec id=\"background\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Renal impairment is a frequent and adverse prognostic factor in multiple myeloma (MM), with dialysis-dependent patients largely excluded from pivotal trials of B-cell maturation antigen (BCMA)-directed therapies. Elranatamab, a BCMA\u00d7CD3 bispecific antibody, has demonstrated significant efficacy in relapsed\/refractory multiple myeloma (RRMM); however, data in end-stage renal disease are extremely limited. We report real-world outcomes of four dialysis-dependent RRMM patients treated with elranatamab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"results\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients with a median age of 67 years (range 61\u201380) had received a median of six prior lines of therapy (range 4\u20137). All were refractory to proteasome inhibitors, immunomodulatory drugs, and anti-CD38 therapy, and none had prior BCMA-directed treatment. Baseline glomerular filtration rate ranged from 5 to 20 mL\/min, and all patients were dialysis-dependent. At data cutoff, all four patients were evaluable for response. Two patients achieved complete response (CR), one achieved very good partial response, and one achieved partial response, resulting in an overall response rate of 100%. Treatment was ongoing in all four patients. Cytokine release syndrome (CRS) occurred in one patient (grade 1) and was self-limited. No immune effector cell-associated neurotoxicity syndrome (ICANS) events were observed. One patient developed severe pneumonia requiring intensive care unit admission; treatment was temporarily interrupted and successfully resumed without step-up dosing, maintaining CR. Hematologic toxicity was limited, with grade-4 lymphopenia in one patient. No dialysis-related complications or unexpected toxicities were observed. All patients received infection prophylaxis after hemodialysis, including trimethoprim\u2013sulfamethoxazole, valacyclovir, and levofloxacin, with intravenous immunoglobulin administered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"conclusion\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this real-world case series of dialysis-dependent RRMM patients, elranatamab demonstrated high response rates, low incidence of CRS, absence of neurotoxicity, and manageable infectious complications. These findings support the feasibility and clinical activity of elranatamab in patients undergoing hemodialysis. Larger prospective studies are warranted to confirm these encouraging results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.46989\/001c.171328","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T13:14:52Z","timestamp":1790601292000},"source":"Crossref","is-referenced-by-count":0,"title":["Elranatamab in relapsed\/refractory multiple myeloma patients on hemodialysis: A real-world case series"],"prefix":"10.46989","volume":"8","author":[{"given":"Hikmettullah","family":"Batgi","sequence":"first","affiliation":[{"name":"Dokuz Eylul University, Faculty of Medicine, Department of Hematology and Bone Marrow Transplantation Unit, Department of Hematology, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fato\u015f","family":"Dilan K\u00f6seo\u011flu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, Bak\u0131r\u00e7ay University, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"\u00c7etin","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ege University School of Medicine, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semih","family":"Ba\u015fc\u0131","sequence":"additional","affiliation":[{"name":"Dokuz Eylul University, Faculty of Medicine, Department of Hematology and Bone Marrow Transplantation Unit, Department of Hematology, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinem","family":"Namdaro\u011flu","sequence":"additional","affiliation":[{"name":"Dokuz Eylul University, Faculty of Medicine, Department of Hematology and Bone Marrow Transplantation Unit, Department of Hematology, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur","family":"Akad Soyer","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ege University School of Medicine, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26435","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"issue":"4","key":"ref1","doi-asserted-by":"publisher","first-page":"e70120","DOI":"10.1002\/hon.70120","article-title":"Elranatamab for Relapsed\/Refractory Multiple Myeloma With Severe Renal Impairment Requiring Hemodialysis","volume":"43","author":"M. Hoffmann","year":"2025","journal-title":"Hematol Oncol"},{"issue":"11","key":"ref2","doi-asserted-by":"publisher","first-page":"6075","DOI":"10.1007\/s00277-025-06689-0","article-title":"Efficacy and safety of bispecific antibodies in multiple myeloma patients with end-stage renal disease undergoing hemodialysis: a case report of elranatamab and a literature review","volume":"104","author":"D. Ogiya","year":"2025","journal-title":"Ann Hematol"},{"issue":"6","key":"ref3","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies","volume":"4","author":"G. Lancman","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"5","key":"ref4","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"P. Rodriguez-Otero","year":"2024","journal-title":"Lancet Oncol"},{"issue":"5","key":"ref5","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.2215\/CJN.00950208","article-title":"Aspects of immune dysfunction in end-stage renal disease","volume":"3","author":"S. Kato","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180660","article-title":"Teclistamab in Relapsed Refractory Multiple Myeloma Patients on Dialysis: A French Experience","author":"Florence Lachenal","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"ref7","doi-asserted-by":"publisher","first-page":"6912","DOI":"10.1182\/blood-2024-201209","article-title":"Safety and Efficacy of Teclistamab in a Patient Series with Relapsed\/Refractory Multiple Myeloma and Severe Renal Impairment on Dialysis","volume":"144","author":"Nutdanai Roila","year":"2024","journal-title":"Blood"},{"issue":"3","key":"ref8","doi-asserted-by":"publisher","first-page":"777","DOI":"10.3324\/haematol.2023.283940","article-title":"Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed\/refractory multiple myeloma with renal impairment","volume":"109","author":"S. Sidana","year":"2024","journal-title":"Haematologica"},{"issue":"16","key":"ref9","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1080\/14656566.2016.1236915","article-title":"Current treatments for renal failure due to multiple myeloma","volume":"17","author":"M. Gavriatopoulou","year":"2016","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"ref10","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1093\/ndt\/gfp488","article-title":"Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre","volume":"25","author":"R. J. Haynes","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"ref11","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38 targeted monoclonal antibody therapy","volume":"33","author":"U. H. Gandhi","year":"2019","journal-title":"Leukemia"},{"issue":"7","key":"ref12","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1200\/OP.21.00327","article-title":"Multiple Myeloma: From Baby Steps to Giant Strides","volume":"17","author":"S. Kumar","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"9","key":"ref13","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"A. M. Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.2217\/fon-2023-0995","article-title":"Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma","volume":"20","author":"L. J. Costa","year":"2024","journal-title":"Future Oncol"},{"issue":"6","key":"ref15","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.hoc.2007.08.006","article-title":"Complications of multiple myeloma","volume":"21","author":"J. Blad\u00e9","year":"2007","journal-title":"Hematol Oncol Clin North Am"},{"issue":"6","key":"ref16","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"P. Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"ref17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.46989\/001c.116800","article-title":"Elranatamab treatment in a multiple myeloma patient undergoing renal dialysis","volume":"6","author":"Z. Van de Wyngaert","year":"2024","journal-title":"Clin Hematol Int"}],"container-title":["Clinical Hematology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/chi.scholasticahq.com\/article\/171328-elranatamab-in-relapsed-refractory-multiple-myeloma-patients-on-hemodialysis-a-real-world-case-series","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T13:14:53Z","timestamp":1790601293000},"score":1,"resource":{"primary":{"URL":"https:\/\/chi.scholasticahq.com\/article\/171328-elranatamab-in-relapsed-refractory-multiple-myeloma-patients-on-hemodialysis-a-real-world-case-series"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":17,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.46989\/001c.171328","relation":{},"ISSN":["2590-0048"],"issn-type":[{"value":"2590-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]}}}